A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score

por Moein, Anita, Langenhorst, Jurgen, Plan, Elodie L., Jin, Jin Y., Kågedal, Matts, Kassir, Nastya
Publicado 2023

Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease

por Yoshida, Kenta, Moein, Anita, Bittner, Tobias, Ostrowitzki, Susanne, Lin, Helen, Honigberg, Lee, Jin, Jin Y., Quartino, Angelica
Publicado 2020

Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis

por Kassir, Nastya, Zhu, Rui, Moein, Anita, Langenhorst, Jurgen, Ribbing, Jakob, Zhang, Rong, Tang, Meina T., Oh, Young S., Zhang, Wenhui
Publicado 2022

Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis

por Moein, Anita, Lu, Tong, Jönsson, Siv, Ribbing, Jakob, Kassir, Nastya, Zhang, Wenhui, Sperinde, Gizette, Zhang, Rong, Tang, Meina, Oh, Young S., Bruno, Rene, Zhu, Rui
Publicado 2022

First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers

por Tang, Fei, Kunder, Rebecca, Chu, Tom, Hains, Avis, Nguyen, Allen, McBride, Jacqueline M., Zhong, Yu, Santagostino, Sara, Wilson, Maria, Trenchak, Abigail, Chen, Liuxi, Ly, Justin, Moein, Anita, Lewin‐Koh, Nicholas, Raghavan, Vibha, Osaghae, Uyi, Wynne, Chris, Owen, Ryan, Place, David
Publicado 2023